182 related articles for article (PubMed ID: 18678345)
1. Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis.
Straumann A; Bussmann C; Conus S; Beglinger C; Simon HU
J Allergy Clin Immunol; 2008 Aug; 122(2):425-7. PubMed ID: 18678345
[No Abstract] [Full Text] [Related]
2. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.
Stein ML; Collins MH; Villanueva JM; Kushner JP; Putnam PE; Buckmeier BK; Filipovich AH; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2006 Dec; 118(6):1312-9. PubMed ID: 17157662
[TBL] [Abstract][Full Text] [Related]
3. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes.
Stasi R; Amadori S
Br J Haematol; 2002 Feb; 116(2):334-7. PubMed ID: 11841434
[TBL] [Abstract][Full Text] [Related]
4. Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis.
Conus S; Straumann A; Bettler E; Simon HU
J Allergy Clin Immunol; 2010 Jul; 126(1):175-7. PubMed ID: 20542323
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of infliximab in active SLE: a pilot study.
Uppal SS; Hayat SJ; Raghupathy R
Lupus; 2009 Jul; 18(8):690-7. PubMed ID: 19502264
[TBL] [Abstract][Full Text] [Related]
6. TNF-α antagonist infliximab in the treatment of depression in older adults: results of a prematurely ended, randomized, placebo-controlled trial.
Maas DW; Westendorp RG; Willems JM; de Craen AJ; van der Mast RC
J Clin Psychopharmacol; 2010 Jun; 30(3):343-5. PubMed ID: 20473080
[No Abstract] [Full Text] [Related]
7. Use of anti-tumor necrosis factor agents: a possible therapy for vitiligo.
Lv Y; Li Q; Wang L; Gao T
Med Hypotheses; 2009 May; 72(5):546-7. PubMed ID: 19201101
[TBL] [Abstract][Full Text] [Related]
8. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab.
Yazdani-Biuki B; Stelzl H; Brezinschek HP; Hermann J; Mueller T; Krippl P; Graninger W; Wascher TC
Eur J Clin Invest; 2004 Sep; 34(9):641-2. PubMed ID: 15379764
[No Abstract] [Full Text] [Related]
9. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Suzuki K; Tanaka Y
Rheumatology (Oxford); 2009 Aug; 48(8):1012-3. PubMed ID: 19465589
[No Abstract] [Full Text] [Related]
10. Infliximab and the TNF-alpha system.
Ebert EC
Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G612-20. PubMed ID: 19136378
[TBL] [Abstract][Full Text] [Related]
11. Reslizumab for pediatric eosinophilic esophagitis.
Walsh GM
Immunotherapy; 2010 Jul; 2(4):461-5. PubMed ID: 20636000
[TBL] [Abstract][Full Text] [Related]
12. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.
Denton CP; Engelhart M; Tvede N; Wilson H; Khan K; Shiwen X; Carreira PE; Diaz Gonzalez F; Black CM; van den Hoogen FH
Ann Rheum Dis; 2009 Sep; 68(9):1433-9. PubMed ID: 18782794
[TBL] [Abstract][Full Text] [Related]
13. Increased HLA-DR expression on tissue eosinophils in eosinophilic esophagitis.
Patel AJ; Fuentebella J; Gernez Y; Nguyen T; Bass D; Berquist W; Cox K; Sibley E; Kerner J; Nadeau K
J Pediatr Gastroenterol Nutr; 2010 Sep; 51(3):290-4. PubMed ID: 20639774
[TBL] [Abstract][Full Text] [Related]
14. Infliximab treatment for resistant Achilles tendonitis.
Al-Asfar SM; Attar M; Shacfeh H
Saudi Med J; 2009 Sep; 30(9):1228-30. PubMed ID: 19750273
[TBL] [Abstract][Full Text] [Related]
15. Exploring the role of mast cells in eosinophilic esophagitis.
Wershil BK
Immunol Allergy Clin North Am; 2009 Feb; 29(1):189-95, xiii. PubMed ID: 19141354
[TBL] [Abstract][Full Text] [Related]
16. [Infliximab].
Herrera E; Habicheyn S
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of refractory Behçet's disease with the TNF-alpha blocker infliximab.
Jalili A; Kinaciyan T; Barisani T; Peck-Radosavljevic M; Stingl G; Geusau A; Wöhrl S
Iran J Immunol; 2009 Mar; 6(1):55-8. PubMed ID: 19293479
[No Abstract] [Full Text] [Related]
18. Infliximab effective in steroid-dependent juvenile eosinophilic fasciitis.
Tzaribachev N; Holzer U; Schedel J; Maier V; Klein R; Kuemmerle-Deschner J
Rheumatology (Oxford); 2008 Jun; 47(6):930-2. PubMed ID: 18417525
[No Abstract] [Full Text] [Related]
19. Successful treatment of eosinophilic esophagitis with ciclesonide.
Schroeder S; Fleischer DM; Masterson JC; Gelfand E; Furuta GT; Atkins D
J Allergy Clin Immunol; 2012 May; 129(5):1419-21. PubMed ID: 22480537
[No Abstract] [Full Text] [Related]
20. Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis.
Onizawa M; Nagaishi T; Kanai T; Nagano K; Oshima S; Nemoto Y; Yoshioka A; Totsuka T; Okamoto R; Nakamura T; Sakamoto N; Tsuchiya K; Aoki K; Ohya K; Yagita H; Watanabe M
Am J Physiol Gastrointest Liver Physiol; 2009 Apr; 296(4):G850-9. PubMed ID: 19179628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
